Get the Stockscreener App
4.04
0.50%
0.02
After Hours:
4.03
-0.010
-0.25%
Checkpoint Therapeutics Inc stock is traded at $4.04, with a volume of 1.33M.
It is up +0.50% in the last 24 hours and up +1.76% over the past month.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
See More
Previous Close:
$4.02
Open:
$4.01
24h Volume:
1.33M
Relative Volume:
0.53
Market Cap:
$338.41M
Revenue:
$103.00K
Net Income/Loss:
$-42.47M
P/E Ratio:
-2.1263
EPS:
-1.9
Net Cash Flow:
$-34.30M
1W Performance:
+1.25%
1M Performance:
+1.76%
6M Performance:
+43.26%
1Y Performance:
+139.05%
1-Day Range:
$4.01
$4.04
1-Week Range:
$3.96
$4.04
52-Week Range:
$1.38
$4.50
Checkpoint Therapeutics Inc Stock (CKPT) Company Profile
Name
Checkpoint Therapeutics Inc
Sector
Industry
Phone
781-652-4500
Address
95 SAWYER ROAD, WALTHAM, NY
Compare CKPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CKPT
Checkpoint Therapeutics Inc
|
4.04 | 338.41M | 103.00K | -42.47M | -34.30M | -1.90 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.89 | 124.91B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
549.28 | 60.05B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
587.59 | 35.88B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
230.50 | 29.83B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
228.14 | 24.58B | 3.81B | -644.79M | -669.77M | -6.24 |
Checkpoint Therapeutics Inc Stock (CKPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-25 | Initiated | D. Boral Capital | Buy |
| Jul-14-22 | Resumed | B. Riley Securities | Buy |
| Jun-09-21 | Initiated | B. Riley Securities | Buy |
| Jan-20-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-29-19 | Initiated | Lake Street | Buy |
| Dec-08-17 | Initiated | H.C. Wainwright | Buy |
View All
Checkpoint Therapeutics Inc Stock (CKPT) Latest News
Checkpoint therapeutics CFO Garrett Gray sells $49,904 in stock By Investing.com - Investing.com South Africa
High Growth Tech Stocks in the US for April 2025 - simplywall.st
3 Growth Companies Insiders Are Betting On - Yahoo Finance
Checkpoint Therapeutics CEO sells stock for $60,963 By Investing.com - Investing.com Canada
Checkpoint therapeutics CFO Garrett Gray sells $49,904 in stock - Investing.com India
Checkpoint Therapeutics CEO sells stock for $60,963 - Investing.com India
Checkpoint Therapeutics Executives Sell Shares for Tax Obligations - TradingView
Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights - The Manila Times
Fortress Biotech Transforms Portfolio: Dual FDA Wins, $28M Deal, Latest Earnings - Stock Titan
Checkpoint Therapeutics Full Year 2024 Earnings: US$1.42 loss per share (vs US$1.87 loss in FY 2023) - Yahoo Finance
Checkpoint Therapeutics Reports 2024 Financial Results and Merger - TipRanks
Checkpoint Therapeutics Inc. (CKPT) reports earnings - Quartz
Checkpoint Therapeutics, Inc. SEC 10-K Report - TradingView
Checkpoint Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates - The Manila Times
Breakthrough: CKPT Secures FDA Approval and $416M Merger Deal in Transformative Year - Stock Titan
GLAZER CAPITAL, LLC Acquires Significant Stake in Checkpoint The - GuruFocus
Beryl Capital Management LLC's Strategic Acquisition of Checkpoi - GuruFocus.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRDG, CMRX, WBA, CKPT on Behalf of Shareholders - Morningstar
Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) Shift From Loss To Profit - Yahoo
Sun Pharma shares in focus as co to acquire Checkpoint Therapeutics for $355 million - MSN
CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc.CKPT - Business Wire
Sun Pharma To Acquire Nasdaq-Listed Checkpoint Therapeutics For $355 Million - MSN
SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Investigation into Fairness of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) Buyout Offer and Encourages Investors to Contact the Firm to Discuss Their Legal Rights and Options - GlobeNewswire
SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Investigation into Fairness of ... - Bluefield Daily Telegraph
SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Investigation into Fairness of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) Buyout Offer and Encourages Investors to Contact the Firm to Discuss Their Legal Rights and Options - GlobeNewswire Inc.
10,081 Shares in Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Bought by SBI Securities Co. Ltd. - Defense World
Sun Pharma is betting big on speciality. Will it pay off? | Stock Market News - Mint
How Acquiring Checkpoint Therapeutics Inc Adds Value to Sun Pharma? - Smartkarma
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Checkpoint Therapeutics, Inc. (NasdaqCKPT), Redfin Corporation (NasdaqRDFN), Amplify Energy Corp. (NYSEAMPY), Blackboxstocks Inc. (NasdaqBL - Morningstar
Sun Pharma to Acquire Checkpoint Therapeutics in Oncology Expansion - Chemical Industry Digest
Checkpoint Therapeutics’ (CKPT) “Neutral” Rating Reaffirmed at HC Wainwright - Defense World
Checkpoint Therapeutics Target of Unusually Large Options Trading (NASDAQ:CKPT) - Defense World
This Lennar Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday - Benzinga
Major Acquisition Deal in Pharmaceutical Industry: Sun Pharma to Acquire Checkpoint Therapeutics - Dalal Street Investment Journal
Sun Pharma to acquire Checkpoint Therapeutics Inc for up to USD 355 mn - Press Trust of India
Sun Pharma shares rise over 2 pc as company to acquire Checkpoint Therapeutics - Press Trust of India
3 Penny Stocks to Watch Now, 11/3/25 - TipRanks
Checkpoint Therapeutics (NASDAQ:CKPT) Receives Hold Rating from Lake Street Capital - Defense World
Sun Pharma surges 3%. 3 reasons why Motilal Oswal has ‘Buy’ rating - The Financial Express
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Checkpoint Therapeutics, Inc.CKPT - The Malaysian Reserve
Sun Pharma to acquire oncology therapy company Checkpoint in US - domain-b.com: The first online Indian business magazine
Checkpoint Therapeutics (NASDAQ:CKPT) Given Buy Rating at D. Boral Capital - Defense World
Sun Pharma to acquire a US-based oncology firm in a deal exceeding ₹3,000 crore - Bizz Buzz
Despite near-term challenges, brokerages remain positive on Sun Pharma - Business Standard
Sun Pharma to acquire US oncology compony for over Rs 3,000 crore - MSN
CKPT Merger Alert: Checkpoint Shareholders Seeking Money Should Contact Julie & Holleman Regarding Sale to Sun Pharma - Longview News-Journal
Checkpoint Therapeutics gets picked up by Sun Pharma, enjoys 60% share bump - Mugglehead Magazine
Small cap wrap: HIVE, North Bay Resources, GoviEx... - Proactive Investors UK
India-Based Sun Pharma To Buy US Cancer Firm Checkpoint Therapeutics: Details - AOL.com
Checkpoint Therapeutics Inc Stock (CKPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Checkpoint Therapeutics Inc Stock (CKPT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GRAY WILLIAM GARRETT | Chief Financial Officer |
Apr 01 '25 |
Sale |
4.05 |
12,322 |
49,904 |
1,446,322 |
| Oliviero James F III | CEO, President and Director |
Feb 10 '25 |
Sale |
3.15 |
10,331 |
32,543 |
3,775,019 |
| Oliviero James F III | CEO, President and Director |
Feb 07 '25 |
Sale |
3.41 |
9,233 |
31,485 |
3,785,350 |
| GRAY WILLIAM GARRETT | Chief Financial Officer |
Feb 06 '25 |
Sale |
3.67 |
74,110 |
271,984 |
1,458,644 |
| Oliviero James F III | CEO, President and Director |
Dec 18 '24 |
Sale |
3.87 |
602,167 |
2,330,386 |
3,414,813 |
| Oliviero James F III | CEO, President and Director |
Dec 19 '24 |
Sale |
3.38 |
220,230 |
744,377 |
3,194,583 |
| GRAY WILLIAM GARRETT | Chief Financial Officer |
Dec 18 '24 |
Sale |
4.01 |
268,432 |
1,076,412 |
1,032,754 |
| Oliviero James F III | CEO, President and Director |
Jun 26 '24 |
Sale |
2.05 |
24,610 |
50,450 |
1,977,170 |
| GRAY WILLIAM GARRETT | Chief Financial Officer |
Jun 26 '24 |
Sale |
2.06 |
13,038 |
26,858 |
672,186 |
0.21%
1.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):